317 related items for PubMed ID: 22226058
1. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP, Hsieh KS, Huang SH, Ou SF, Ma CY, Ho TY, Lai CR, Ger LP.
Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
[Abstract] [Full Text] [Related]
2. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
3. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[Abstract] [Full Text] [Related]
4. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[Abstract] [Full Text] [Related]
5. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[Abstract] [Full Text] [Related]
6. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
7. [Risk factors for coronary artery lesions in children with Kawasaki disease].
Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
[Abstract] [Full Text] [Related]
8. Facial nerve palsy may indicate coronary artery lesions in Kawasaki disease.
Chen J, Liu P, Hu W, Xu Y, Deng J.
Clin Rheumatol; 2021 Oct; 40(10):4191-4197. PubMed ID: 34059986
[Abstract] [Full Text] [Related]
9. The role of serum lipid in predicting coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease: a cohort study.
Zhang H, Cai J, Zhang R, Shuai S, Tang M, Ju R, Hu Y, Zuo T, Yang Y.
J Int Med Res; 2024 May; 52(5):3000605241252115. PubMed ID: 38713460
[Abstract] [Full Text] [Related]
10. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
11. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
[Abstract] [Full Text] [Related]
12. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
J Pediatr; 2000 Aug 21; 137(2):177-80. PubMed ID: 10931408
[Abstract] [Full Text] [Related]
13. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Wang JR, Zhao HZ, Chang LJ, Xu X, Gao Y, Li M, Kong QY, Wang MM, Zhao CF.
Eur J Pediatr; 2023 Oct 21; 182(10):4399-4406. PubMed ID: 37480545
[Abstract] [Full Text] [Related]
14. Expression of receptor for advanced glycation end products (RAGE) on the surface of circulating endothelial cells is upregulated in Kawasaki disease.
Gong F, Zhang Y, Xie C, Zhu W, Wang W, Fu S, Shen H.
Pediatr Res; 2012 Jun 21; 71(6):720-4. PubMed ID: 22337222
[Abstract] [Full Text] [Related]
15. Interleukin-18 and coronary artery lesions in patients with Kawasaki disease.
Weng KP, Hsieh KS, Huang SH, Ou SF, Lai TJ, Tang CW, Lin CC, Ho TY, Liou HH, Ger LP.
J Chin Med Assoc; 2013 Aug 21; 76(8):438-45. PubMed ID: 23769880
[Abstract] [Full Text] [Related]
16. [Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin].
Mori M.
Nihon Rinsho; 2008 Feb 21; 66(2):349-54. PubMed ID: 18260334
[Abstract] [Full Text] [Related]
17. Difference in Risk Factors for Subtypes of Acute Cardiac Lesions Resulting from Kawasaki Disease.
Yamashita M, Ae R, Yashiro M, Aoyama Y, Sano T, Makino N, Nakamura Y.
Pediatr Cardiol; 2017 Feb 21; 38(2):375-380. PubMed ID: 27878631
[Abstract] [Full Text] [Related]
18. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec 21; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
19. [Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].
Liu F, Ding Y, Yin W.
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Dec 21; 15(12):1109-12. PubMed ID: 24342209
[Abstract] [Full Text] [Related]
20. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
Cardiovasc Ther; 2021 Dec 21; 2021():6660407. PubMed ID: 34239607
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
